CLINICAL_TRIALS
trial_result
· 2022-03-09
Clinical Trial Update: Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia [Phase 2]
Summary
Phase 2 clinical trial of adjunctive therapy with AR-105 (Aerucin) for Pseudomonas aeruginosa pneumonia has completed and results were posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Aridis Pharmaceuticals, Inc. | Conditions: Pseudomonas Aeruginosa Pneumonia | Phase 2 | Status: COMPLETED | Results posted: 2022-03-09